Third Rock Ventures — Pre-Seed & Seed VC Firm ($500K–$15.0M Checks)
Third Rock Ventures is a Pre-Seed, Seed, Series A venture capital firm based in Boston, MA investing in Healthcare, Other. The firm typically writes $500K–$15.0M checks and has 8 portfolio companies in our records.
- Check size
- $500K–$15.0M
- Portfolio
- 8 companies on record
- Partners
- 11 listed
- AUM
- $3.8B
- Stage
- Pre-Seed, Seed, Series A
- Sectors
- Healthcare, Other
- HQ
- Boston, MA
Last verified: 2026-06-19
Pre-Seed, Seed, Series A
$500K – $15.0M
$3.8B
8+ companies
11 partners
Investment Thesis
Third Rock focuses exclusively on life sciences companies with transformative therapeutic potential, particularly in oncology and precision medicine.
How Third Rock Ventures invests
Third Rock Ventures is a vc firm based in Boston, MA. The firm invests at the Pre-Seed, Seed, Series A stages, with a focus on Healthcare, Other.
Third Rock Ventures typically writes checks of $500K–$15.0M per investment, backed by approximately $3.8B in assets under management.
Third Rock Ventures has backed 8 companies in our records, including Allogene Therapeutics, Neon Therapeutics, Aqvesme™.
Partners & Team
Christoph Westphal
Founding Partner
Industry Focus
Invests In
Portfolio Companies (8)
Other
Allogene Therapeutics
Neon Therapeutics
Aqvesme™
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
Syremis Therapeutics
Syremis is developing novel medicines to make a profound impact on the treatment of mental health.
INLEXZO™
INLEXZO™ (gemcitabine intravesical system) an original asset from Taris Bio, receives FDA approval.
Azalea Therapeutics
Azalea is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo.
Element Science
Element Science receives FDA approval for the revolutionary Jewel® Patch Wearable Cardioverter Defibrillator.
Merida Biosciences
Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers.
- •Raising at Pre-Seed, Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare, Other — the sectors they actively back.
- •Size your ask to their typical $500K – $15.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Alison Connors, Chief Financial Officer.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Third Rock Ventures is a match for your startup
Upload your pitch deck to see how well you match with Third Rock Ventures and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal